[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"RSUP Persahabatan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100629895","efficacy-of-indonesian-asthmatic-gymnastic-as-combine-pulmonary-rehabilitation-based-on-asthma-classification-100629895",false,"NCT07480616","Efficacy of Indonesian Asthmatic Gymnastic as Combine Pulmonary Rehabilitation Based on Asthma Classification","EFFICACY OF INDONESIAN ASTHMATIC GYMNASTIC AS COMBINE PULMONARY REHABILITATION IN ASTHMATIC PATIENT BASED ON ASTHMA CLASSIFICATION","Inclusion Criteria:\n\n* Diagnosed with stable asthma\n* Age 18-65 years old\n* Competent and willing to be included in the trial\n\nExclusion Criteria:\n\n* Asthma exacerbation\n* Had other lung disease\n* Had neuromuscular disease affecting respiratory system","ALL","18 Years","65 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the efficacy of Indonesian Asthma Gymnastic for stable asthmatic patients in all asthma classification. The outcome measurements includes 6 minutes walk test, Asthma Control Test, peak flow rate value, and lung function. All participants have been in routine standard treatment of asthma (medication, education of healthy life style and smoking cessation).",[27,28],"Asthma (Diagnosis)","Adult","RECRUITING","2026-03-13",{"date":32,"type":33},"2026-03-18","ACTUAL",{"date":35,"type":33},"2025-10-06",{"date":37,"type":21},"2026-09",{"name":39,"class":40},"RSUP Persahabatan","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100626868","phase-2-umbilical-cord-mesenchymal-stem-cells-as-adjuvant-therapy-in-group-e-copd-patients-100626868","NCT07441226","Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients","A Randomized, Double-Blind, Controlled Trial of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients","UCMSC-COPD","Inclusion Criteria:\n\n* Adults aged 40 to 75 years.\n* Diagnosed with Group E Chronic Obstructive Pulmonary Disease (COPD) according to GOLD 2023 criteria.\n* Receiving triple inhalation therapy (long-acting beta-agonist, inhaled corticosteroid, long-acting muscarinic antagonist) for at least 6 months prior to enrollment.\n* Clinically stable for at least 2 weeks prior to enrollment.\n* Provided written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Current smoker or stopped smoking less than 6 months prior to screening.\n* Acute exacerbation of COPD within 2 weeks prior to enrollment.\n* Diagnosis of pulmonary diseases other than COPD, including tuberculosis, pulmonary embolism, pneumothorax, multiple bullae, asthma, interstitial lung disease, or lung cancer.\n* History of tuberculosis within the past 10 years.\n* Active infection (including HIV positive).\n* Malignancy of any type.\n* Severe cardiac disease, including congestive heart failure classified as NYHA class III or IV, significant arrhythmias, valvular heart disease, cardiomyopathy, or congenital heart disease.\n* Severe hepatic dysfunction (SGOT, SGPT, or bilirubin levels \\>2 times upper limit of normal).\n* Severe renal dysfunction (serum creatinine \\>1.5 times upper limit of normal).\n* Pregnant or breastfeeding.\n* Comorbid conditions that may affect survival (e.g., advanced diabetes mellitus with HbA1c \\>7%, recent myocardial infarction, unstable angina, liver cirrhosis, acute glomerulonephritis).\n* Leukopenia (white blood cell count \\\u003C4×10⁹\u002FL) or agranulocytosis (white blood cell count \\\u003C1.5×10⁹\u002FL or neutrophils \\\u003C0.5×10⁹\u002FL).\n* History of psychiatric illness, epilepsy, or other central nervous system disorders.\n* History of alcohol or drug abuse.\n* Participation in another clinical trial within 3 months prior to enrollment.\n* Poor adherence to prior medical care or expected difficulty completing the study protocol.\n* Inability to perform spirometry maneuvers.\n* Life expectancy less than 6 months due to comorbid conditions.\n* Use of immunosuppressive therapy within 8 months prior to screening.","40 Years","75 Years",{"count":53,"type":21},20,[55],"PHASE2","This study aims to evaluate the efficacy and safety of allogeneic human UC-MSC to treat stage E Chronic Obstructive Pulmonary Disease (COPD).\n\nAll participants in this study already receive standard treatment for COPD, which includes triple inhaled medications with LABA, LAMA and ICS.\n\nWe hypothesize that UC-MSCs will improve COPD management. UC-MSCs are prepared in a certified laboratory and given intravenously. For 12 months from day 0, all patients will be observed for comprehensive safety evaluation, pulmonary function testing (PFT), quality of life indicators including questionnaires, 6-min walk test (6MWT), and inflammation biomarkers.",[58],"Chronic Obstructive Pulmonary Disease (COPD)","2026-02-24",{"date":61,"type":33},"2026-02-27",{"date":63,"type":33},"2025-08-08",{"date":65,"type":21},"2028-01",{"name":39,"class":40},""]